<DOC>
	<DOC>NCT02913716</DOC>
	<brief_summary>This study assesses the mass balance recovery, pharmacokinetics, metabolite profile and metabolite identification of defactinib.</brief_summary>
	<brief_title>A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Body mass index (BMI) 18.0 to 35.0 kg/m2 History (Hx) regular bowel movements Creatinine clearance &gt;80 mL/min Hx alcohol abuse in past 2 yrs Current smoker Systolic blood pressure (S) or diastolic blood pressure (DBP) above upper limit of reference range (age 4044 &gt;90/140; age 4565 &gt;90/150)</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>